Literature DB >> 31014995

Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses.

Daniele Piovani1, Silvio Danese1, Laurent Peyrin-Biroulet2, Georgios K Nikolopoulos3, Theodore Lytras4, Stefanos Bonovas5.   

Abstract

BACKGROUND & AIMS: Multiple environmental factors have been associated with the development of inflammatory bowel diseases (IBDs). We performed an umbrella review of meta-analyses to summarize available epidemiologic evidence and assess its credibility.
METHODS: We systematically identified and appraised meta-analyses of observational studies examining environmental factors and risk of IBD (Crohn's disease [CD] or ulcerative colitis [UC]). For each meta-analysis, we considered the random effects estimate, its 95% confidence interval, the estimates of heterogeneity, and small-study effects, and we graded the evidence according to prespecified criteria. Methodologic quality was assessed with AMSTAR (ie, A Measurement Tool to Assess Systematic Reviews) 2.
RESULTS: We examined 183 estimates in 53 meta-analyses of 71 environmental factors related to lifestyles and hygiene, surgeries, drug exposures, diet, microorganisms, and vaccinations. We identified 9 factors that increase risk of IBD: smoking (CD), urban living (CD and IBD), appendectomy (CD), tonsillectomy (CD), antibiotic exposure (IBD), oral contraceptive use (IBD), consumption of soft drinks (UC), vitamin D deficiency (IBD), and non-Helicobacter pylori-like enterohepatic Helicobacter species (IBD). We identified 7 factors that reduce risk of IBD: physical activity (CD), breastfeeding (IBD), bed sharing (CD), tea consumption (UC), high levels of folate (IBD), high levels of vitamin D (CD), and H pylori infection (CD, UC, and IBD). Epidemiologic evidence for all of these associations was of high to moderate strength; we identified another 11 factors associated with increased risk and 16 factors associated with reduced risk with weak credibility. Methodologic quality varied considerably among meta-analyses. Several associations were based on findings from retrospective studies, so it is not possible to determine if these are effects of IBD or the results of recall bias.
CONCLUSIONS: In an umbrella review of meta-analyses, we found varying levels of evidence for associations of different environmental factors with risk of IBD. High-quality prospective studies with analyses of samples from patients with recent diagnoses of IBD are needed to determine whether these factors cause or are results of IBD and their pathogenic mechanisms.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Intestine; Pathogenesis; Summary

Mesh:

Year:  2019        PMID: 31014995     DOI: 10.1053/j.gastro.2019.04.016

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  100 in total

1.  Appendectomy in childhood-did it save my sibling from getting ulcerative colitis?

Authors:  Niels Teich; Tony Bruns; Andreas Stallmach
Journal:  Int J Colorectal Dis       Date:  2020-10-23       Impact factor: 2.571

2.  Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.

Authors:  Shilpa Grover; Michael Dougan; Kevin Tyan; Anita Giobbie-Hurder; Steven M Blum; Jeffrey Ishizuka; Taha Qazi; Rawad Elias; Kruti B Vora; Alex B Ruan; William Martin-Doyle; Michael Manos; Lauren Eastman; Meredith Davis; Maria Gargano; Rizwan Haq; Elizabeth I Buchbinder; Ryan J Sullivan; Patrick A Ott; F Stephen Hodi; Osama E Rahma
Journal:  Cancer       Date:  2020-06-22       Impact factor: 6.860

3.  OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment.

Authors:  Ziyang Chen; Xiaogang Zhang; Zhe Xing; Shuaijun Lv; Linxuan Huang; Jingping Liu; Shubiao Ye; Xinyao Li; Meiqi Chen; Shaowen Zuo; Yingxu Tao; Yumei He
Journal:  Oncogene       Date:  2022-04-29       Impact factor: 9.867

4.  Risk Factors for Vitamin D Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Shanzhen Shi; Jiaxing Feng; Lixiang Zhou; Yu Li; Huaxiu Shi
Journal:  Turk J Gastroenterol       Date:  2021-06       Impact factor: 1.852

Review 5.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

6.  Systematic review: gastrointestinal infection and incident inflammatory bowel disease.

Authors:  Jordan E Axelrad; Ken H Cadwell; Jean-Frederic Colombel; Shailja C Shah
Journal:  Aliment Pharmacol Ther       Date:  2020-05-05       Impact factor: 8.171

7.  16S rRNA sequencing analysis: the devil is in the details.

Authors:  Amy M Tsou; Scott W Olesen; Eric J Alm; Scott B Snapper
Journal:  Gut Microbes       Date:  2020-04-24

Review 8.  Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD).

Authors:  Vincenzo Villanacci; Luca Reggiani-Bonetti; Tiziana Salviato; Giuseppe Leoncini; Moris Cadei; Luca Albarello; Alessandro Caputo; Maria Costanza Aquilano; Serena Battista; Paola Parente
Journal:  Pathologica       Date:  2021-02

9.  Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases.

Authors:  Chun-Han Lo; Hamed Khalili; Mingyang Song; Paul Lochhead; Kristin E Burke; James M Richter; Edward L Giovannucci; Andrew T Chan; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-03       Impact factor: 11.382

10.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.